What NeoGenomics (NEO) Said on Its Q3 Earnings Call

NeoGenomics NASDAQ: NEO reported third-quarter revenue growth of 11% year over year, led by continued expansion in next-generation sequencing, or NGS, testing, while raising its full-year revenue and adjusted EBITDA guidance.

MarketBeat • 18 hours ago

NeoGenomics, Inc. (NEO) Q3 2026 Earnings Call Transcript

NeoGenomics, Inc. (NEO) Q3 2026 Earnings Call Transcript

Seeking Alpha • 21 hours ago

NeoGenomics Reports Third Quarter 2026 Results

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its third-quarter results for the period ended September 30, 2026.

Business Wire • Oct 28, 2026

NeoGenomics (NEO) Q3 Earnings and Revenues Beat Estimates

NeoGenomics (NEO) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.03 per share a year ago.

Zacks Investment Research • a day ago

NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics expanded its partnership with Indica Labs to scale AI-powered digital pathology and support more timely, consistent diagnostic insights.

Business Wire • Oct 15, 2026

NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its third quarter 2026 financial results after the close of the U.S. financial markets on Wednesday, October 28, 2026.

Business Wire • Oct 14, 2026

What's Going On With NeoGenomics Stock Tuesday?

Precision medicine and oncology diagnostics provider NeoGenomics Inc. (NASDAQ:NEO) on Monday announced an executive succession plan and preliminary third-quarter financial results for the period ended Sept. 30, 2026.

Benzinga • Oct 6, 2026

Stryker, Neogenomics Announce CEO Transitions; But One Stock Dives

Stryker and Neogenomics stocks diverged Tuesday after the medtech companies announced their chief executives would soon step down.

Investors Business Daily • Oct 6, 2026

NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its executive leadership and board of directors succession plan.

Business Wire • Oct 5, 2026

NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference

NeoGenomics NASDAQ: NEO executives outlined the company's strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease testing and workflow tools designed for physicians treating patients closer to home.

MarketBeat • Sep 21, 2026